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Abstract
Background: Pendred syndrome (PDS, MIM #274600) is an autosomal recessive disorder characterized by congenital
sensorineural hearing loss and goiter. In this study, we describing the possible PDS causal mutations in a Malaysian
family with 2 daughters diagnosed with bilateral hearing loss and hypothyroidism.
Methods and Results: Whole exome sequencing was performed on 2 sisters with PDS and their unaffected parents.
Our results showed that both sisters inherited monoallelic mutations in the 2 known PDS genes, SLC26A4
(ENST00000265715:c.1343C > T, p.Ser448Leu) and GJB2 (ENST00000382844:c.368C > A, p.Thr123Asn) from their
father, as well as another deafness-related gene, SCARB2 (ENST00000264896:c.914C > T, p.Thr305Met) from their
mother. We postulated that these three heterozygous mutations in combination may be causative to deafness, and
warrants further investigation. Furthermore, we also identified a compound heterozygosity involving the DUOX2 gene
(ENST00000603300:c.1588A > T:p.Lys530* and c.3329G > A:p.Arg1110Gln) in both sisters which are inherited from both
parents and may be correlated with early onset of goiter. All the candidate mutations were predicted deleterious by in
silico tools.
Conclusions: In summary, we proposed that PDS in this family could be a polygenic disorder which possibly arises
from a combination of heterozygous mutations in SLC26A4, GJB2 and SCARB2 which associated with deafness, as well
as compound heterozygous DUOX2 mutations which associated with thyroid dysfunction.
Keywords: Pendred syndrome, Exome sequencing, Syndromic hearing loss, Childhood deafness, Autosomal recessive
inheritance
Background
Hearing loss is a multifactorial disease with nearly 50%
of cases being heritable and attributable to genetic de-
fects [1]. The annual incidence of congenital deafness is
estimated to be 1:1000 newborns [2], hence, identifica-
tion of the heritable causal genes is pivotal to reduce the
incidence of childhood deafness. Pendred syndrome
(PDS, MIM #274600) is among the most common types
of syndromic hearing impairment, and accounts for ap-
proximately 10% of hereditary deafness [3]. PDS is clinic-
ally characterized by sensorineural deafness, enlargement
of the vestibular aqueduct (EVA), goiter, and incomplete
iodide organification [3, 4]. Even though PDS could be
clinically confirmed with perchlorate discharge test in
combination with temporal bone scan of the ear architec-
ture, misdiagnosis with other deafness associated disease
remains as the key challenge [5]. Late onset of goiter
manifestation which usually develops after the age of
10 years and the presentation of only mild hypothyroidism
have made definitive diagnosis of PDS difficult [6, 7].
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Furthermore, the degree of hearing loss could vary from
mild to profound, either contributed by physical malfor-
mation or genetic defects. The limitations to getting an ac-
curate diagnosis will prevent early treatment and may lead
to mental retardation which is preventable by thyroxine
replacement therapy [8]. As such, identification of genes
contributed to PDS is desirable to pave the way towards
early detection of PDS as well as for carrier testing.
PDS is a complex genetic disease which may be inher-
ited monogenically or digenically [4, 9–11]. It has been
well documented that biallelic mutations in SLC26A4
(MIM #605646) is the hallmark of PDS, with a frequency
of 25% [4, 9]. Clinically, SLC26A4 mutation has been
used as genetic test to differentiate between PDS and
non-syndromic familial EVA, which otherwise would not
be possible to clinically distinguish, even with perchlorate
discharge test [6, 12]. However, nearly 50% probands har-
boured only monoallelic mutation in SLC26A4, and for
some patients, PDS is not due to SLC26A4 gene mutations
[4]. The discovery of the involvement of other deafness
genes, including FOXI1 (MIM #601093), KCNJ10 (MIM #
602208) and GJB2 (MIM #121011) [9–11] in combination
with SLC26A4 monoallelic mutation has proposed the ex-
istence of digenic inheritance pattern in PDS and EVA.
The complexity of the genetic defects attributed to PDS
suggests that a comprehensive mutational screening is
warranted to identify the disease causal genes.
In the past, limitations in genomic sequencing technolo-
gies have only permitted the identification of disease-
causing mutations through the candidate gene screening
approach. Now, with the advent of next generation se-
quencing technologies, genome wide screening can now
be performed in a cost-effective manner. Among these,
whole exome sequencing (WES) is preferable as it focuses
only on coding regions in which ~85% disease-causing
mutations are located [13]. WES has also successfully dis-
covered genes for many rare diseases [14]. Given that the
genetic makeup of PDS remains largely unknown and
complex, we performed WES to identify the genes respon-
sible for PDS in a family with 2 affected siblings and their
unaffected parents. This study will enhance our under-
standing about the genetic aetiology underpinning PDS,
and to identify candidate genes which may be useful for
precise molecular diagnosis and to guide family planning
for better management of heritable deafness.
Methods
Subjects
Two siblings diagnosed to have PDS were referred for
molecular evaluation and confirmation of diagnosis.
These sisters were the only children of a pair non-
consanguineous parents. They were 15 and 9 years old
respectively at the time of referral.
Elder sister
The elder sister first presented to her local doctor at the
age of 10 months with progressively enlarging goiter. In-
vestigation then showed hypothyroidism and L-thyroxin
was started. At 3 years of age, her parents noted profound
hearing impairment for which she required hearing aid.
There was no other significant past medical or surgical his-
tory and she was not on any long term medications. Her
parents reported that she had normal speech development
and was able to attend normal school. On examination,
she had a large, diffused multinodular goiter. Ultrasound of
the thyroid gland revealed multiple complex cysts. Tc99m
thyroid scan showed a hyperfunctioning multinodular goi-
ter with increased total iodine uptake of 34.6%. These find-
ings were consistent with dyshormonogenesis (goitrous
hypothyroidism with increased radioactive iodine uptake
by the thyroid). Unfortunately, perchlorate discharge test
could not be done. Hearing test confirmed bilateral pro-
found sensorineural hearing loss > 60 dB, worse for high
frequency sounds. Magnetic resonance image (MRI) of the
inner ear and temporal bones showed bilateral dilated
vestibular aqueduct and presence of only 1 ½ turns of the
cochlear (normal: 2 ¾ turns) consistent with cochlear
hypoplasia. In view of the large goiter size, patient under-
went total thyroidectomy at 13 years of age. Currently she
is receiving full dose of thyroxin i.e. 100 mcg daily.
Younger sister
The younger sister presented with profound hearing loss
at 10 months of age associated with delayed speech de-
velopment. At 16 months, she was wearing hearing aid
and receiving speech therapy. She underwent cochlear
implantation at 5 years of age. Her parents also noticed
progressively enlarging goiter then. She had delayed
speech development. She used sign language for com-
munication and attended special school. On examin-
ation, there was a large, diffused multinodular goiter.
Ultrasound revealed multiple complex cysts within the
thyroid gland. Tc99m thyroid scan showed a hyperfunc-
tioning multinodular goiter with increased total iodine
uptake of 30.4%. Hearing test showed bilateral profound
sensorineural hearing loss > 60 dB, worse for high fre-
quency sounds. MRI of the inner ear and temporal
bones showed bilateral dilated vestibular aqueduct and
presence of only 1 ½ turns of the cochlear (normal 2 ¾
turns) consistent with cochlear hypoplasia. Total thy-
roidectomy was anticipated.
Exome library construction and sequencing
Peripheral blood samples were collected from all the in-
dividuals included in this study with written informed
consent. Genomic DNA was extracted from peripheral
blood using salt extraction method and the DNA quality
was assessed using agarose gel electrophoresis. The
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DNA samples were of good quality (A260/A280 > 2.0;
A260/A230 > 2.0) as assessed by Nanodrop (Thermo
Fisher Scientific, USA). The DNA concentration was
measured using Qubit dsDNA BR Assay Kit (Thermo
Fisher Scientific, USA). The DNA libraries were pre-
pared employing the Ion AmpliSeq™ Exome RDY Kit
(Thermo Fisher Scientific, USA) and were then se-
quenced by the Ion Proton™ System (Thermo Fisher Sci-
entific, USA), according to the manufacturer’s protocol.
Bioinformatic data analysis
Read mapping and variant calling were performed by the
Ion TorrentSuite™ v4.4.2 software (Thermo Fisher Scien-
tific, USA) using default parameters setting. The reads
were aligned to human reference genome hg19, followed
by variant calling using TorrentSuite™ Variant Caller
v4.4.2.1. Next, the variants with SNP quality scores ≤ 30
were filtered out using SnpSift [15], followed by annota-
tion with ANNOVAR [16]. Only non-synonymous vari-
ants in the coding regions (exonic, splicing) with a read
depth greater than 5X were retained for further analysis.
Polymorphisms with allele frequencies > 0.01 reported in
1000 Genomes Project, NHLBI Exome Sequencing Pro-
ject, and Maximum Population Frequency were filtered
out. Subsequently, we identify the candidate disease
causing mutation by comparing the variants detected in
affected sisters with their parents based on monogenic
(autosomal recessive), followed by digenic and polygenic
inheritance traits. Variants which fulfilled the above cri-
teria were manually inspected using Integrative Genom-
ics Viewer to filter out false positive variants [17, 18].
The effect of the variants was assessed using several in
silico prediction tools, including SIFT [19], Polyphen2
[20], MutationTaster [21], FATHMM [22], CADD [23],
PROVEAN [24], and DANN [25]. Candidate mutations
which predicted deleterious by one of the above tools
were further studied by searching literature database.
Sanger validation
A total of 5 predicted pathogenic candidate mutations, i.e.
SLC26A4 (ENST00000265715:c.1343C > T, p.Ser448Leu),
GJB2 (ENST00000382844:c.368C > A, p.Thr123Asn),
SCARB2 (ENST00000264896:c.914C > T, p.Thr305Met),
DUOX2 (ENST00000603300:c.1588A > T, p.Lys530*), and
DUOX2 (ENST00000603300:c.3329G >A, p.Arg1110Gln)
were selected for validation by Sanger sequencing. The
primers were designed using Primer3 (Additional file 1:
Table S4). The regions were amplified by PCR using
AmpliTaq Gold Polymerase (Thermo Fisher Scientific,
USA), and the amplified products were purified using
PCR Purification Kit (Qiagen, Germany), and sequenced
using ABI BigDye Terminator v3.1 Cycle Sequencing Kit
(Thermo Fisher Scientific, USA). The chromatograms
were visualized using BioEdit software.
Results
Whole-exome sequencing
We sequenced the exomes of 4 individuals from a family
with 2 daughters diagnosed with PDS and their unaffected
parents. An average of 36 million reads were generated
per sample, and the reads were mapped to the human ref-
erence genome hg19, with 91% of the bases covered at >
20X coverage. The mean depth of coverage was 104X with
a uniformity of 91%. The variants were filtered as de-
scribed in the Materials and Methods, and the summary
of the sequencing results are as shown in Table 1.
Identification of disease causing genes in Pendred
syndrome
After filtering out polymorphisms with allele frequency >
0.01 as reported in the 1000 Genomes Project, 6500
NHLBI exome and Maximum Population Frequency data-
bases, we retained only non-synonymous variants for
identifying PDS causative mutations. Subsequently, we fil-
tered the variants based on monogenic autosomal reces-
sive trait. Variants which present in both sisters were
prioritized for further investigations. Our analysis identi-
fied DUOX2 (MIM #606759) compound heterozygous
mutations (ENST00000603300: p.Lys530X, p.Arg1110Gln)
were inherited by both sisters from their father and
mother respectively, and may be causative to goiter mani-
festation. However, we did not find additional homozy-
gous or compound heterozygous mutations which may be
contributed to the deafness phenotype.
By taking into consideration that PDS could be inherited
via digenic trait, we then look into heterozygous mutations
which were inherited by both sisters from their unaffected
parents. Interestingly, both sisters inherited missense mu-
tations in 2 genes which known to be associated with PDS
(i.e. SLC26A4: ENST00000265715:c.1343C > T,p.Ser448-
Leu; GJB2: ENST00000382844:c.368C >A, p.Thr123Asn)
from their father, as well as another deafness gene,
SCARB2 (ENST00000264896:c.914C > T,p.Thr305Met)
from their mother. These 3 candidate mutations were pre-
dicted pathogenic by one of the variant effect prediction
tools (i.e. SIFT, Polyphen-2, MutationTaster, FATHMM,
CAAD, PROVEAN and DANN; Additional file 2: Table S1
and Additional file 3: Table S2), hence we postulated that
the combination of these 3 candidate missense mutations
may be contributed to PDS and associated with hearing
loss phenotype. It is noteworthy to mention that SCARB2
could be a novel PDS candidate gene and needs further
investigation.
Furthermore, we also looked into the autosomal reces-
sive mutations which are present only in either probands.
As depicted in Table 2, each sisters harboured additional
non-shared compound heterozygous mutations, however
none of these candidate genes are known to be implicated
in PDS. Further analysis on heterozygous mutations
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(Additional file 2: Table S1 and Additional file 3: Table S2)
found that the elder sister harboured additional mutations
which may be contributed to the PDS phenotype (Add-
itional file 4: Table S3), including hearing (inherited from
father: DIAPH3, GPR171, LOXHD1; inherited from
mother: MCOLN3, SYNE4), and thyroid function (inher-
ited from father: C16orf89; inherited from mother:
TXNDC11). However, these additional mutations have not
exaggerated the manifestation of the hearing loss or goiter,
in which both sisters were diagnosed with bilateral hearing
loss and presented with goiter during 1 year old. Hence,
we postulated that these additional mutations which
present only in elder sister may not be relevant to PDS.
Sanger validation
Candidate genes predicted to be associated with PDS were
selected for further validation by Sanger sequencing. Mu-
tations which were present in both sisters and father
(SLC26A4: c.1343C > T, p.Ser448Leu; GJB2:c.368C > A,
p.Thr123Asn; DUOX2: c.1588A > T, p.Lys530*), and
present in both sisters and mother (SCARB2: c.914C > T,
p.Thr305Met; DUOX2: c.3329C >A, p.Arg1110Gln) were
confirmed. The chromatograms are depicted in Fig. 1.
As summarized in Fig. 2, the father was a heterozy-
gous carrier for SLC26A4, GJB2 and DUOX2, whereas
mother was a heterozygous carrier for SCARB2 and
DUOX2. Both of the sisters harboured the same hetero-
zygous mutations in SLC26A4, GJB2 and SCARB2,
hence suggesting that the combination of these 3 hetero-
zygous mutations may led to hearing loss in these pa-
tients. Furthermore, DUOX2 compound heterozygous
mutation may be associated with early onset of hypothy-
roidisms and goiter.
Discussion
Clinically, PDS is characterized by the manifestation of a
combination of severe to profound sensorineural hearing
loss, inner ear anomalies such as Mondini’s dysplasia,
EVA or vestibular anomalies, and goiter [26–28]. Also,
deafness in PDS generally profound (>60 dB) with pre-
lingual onset [29], and sometimes a fluctuating but
worsening course [30–32], consistent with a progressive
Table 1 Results of exome sequencing of 2 affected sisters and their unaffected parents
Parameter Elder sister Younger sister Father Mother
Mapped reads 42766143 24025346 37859563 40082904
On-target 95.42% 95.48% 96.65% 96.62%
Mean coverage 120.5X 68.36X 111.5X 117X
20X coverage 92.97% 85.20% 91.95% 93.72%
Uniformity 90.95% 91.24% 90.68% 92.24%
No. of total variants 53753 52397 52433 53316
No. of total variants with quality score≥ 30 51907 49251 51016 51941
No. of coding variants 21276 20200 20839 21059
No. of nonsynonymous variants 10703 10156 10454 10563
After removal of polymorphisms 796 797 731 688
Shared Candidate PDS mutations
Homozygous 1 1 0 0
Compound heterozygous 2 2 0 0
Heterozygous inherited from father 132 132 132 NA
Heterozygous inherited from mother 121 121 NA 132
Candidate PDS mutations in elder sister only
Homozygous 0 NA NA NA
Compound heterozygous 5 NA NA NA
Heterozygous inherited from father 73 NA 73 NA
Heterozygous inherited from mother 83 NA NA 83
Candidate PDS mutations in younger sister only
Homozygous NA 0 0 0
Compound heterozygous NA 3 0 0
Heterozygous inherited from father NA 80 80 NA
Heterozygous inherited from mother NA 73 NA 73
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lesion of the sensory organ. In this case study, clinical
diagnosis confirmed both sisters were PDS: (1) MRI
examination of the inner ear confirmed both sisters had
EVA, an essential prerequisite for the diagnosis of PDS
[33, 34]; (2) both sisters had bilateral sensorineural hear-
ing loss, with frequency > 60 dB; (3) both sisters are eu-
thyroid and diagnosed with hypothyroidism at age of
1 year old; (4) the disease is potentially heritable via
autosomal recessive or digenic/polygenic traits as both
sisters are affected whilst their parents were unaffected.
It has been long considered that PDS is a monogenic
disease attributed to SLC46A4 biallelic mutations [35,
36] or a digenic disease attributed to a combination of
SLC46A4 and KCNJ10, FOXI1 or GJB2 [9–11]. Notably,
our analysis did not detect homozygous or compound
heterozygous in the known PDS genes (i.e. SLC26A4,
KCNJ10, FOX1, GJB2) based on monogenic autosomal
recessive trait, hence suggesting PDS in this family could
be a more complex digenic or polygenic disorder. Inter-
estingly, both sisters were found inherited SLC26A4 and
GJB2 monoallellic mutation from their unaffected father.
Loss of function in both SLC26A4 and GJB2 have been
implicated in syndromic and non-syndromic hearing loss
[10, 37, 38]. Whilst SLC26A4 defects mainly attributed
to syndromic hearing loss, GJB2 mutations accounts for
up to 50% of all recessive non-syndromic hearing loss
based on ethnic background [39]. Essentially, SLC26A4
involves in maintaining the endocochlear potential
[35, 36], whereas GJB2 play role in auditory transduc-
tion by recycling potassium ions back to the endolymph
of the cochlear duct [40]. Given that both genes play
pivotal roles in maintaining normal hearing function, we
postulated that the SLC26A4 and GJB2 missense muta-
tions are among the PDS driver mutations in this family.
In addition, in contrast with earlier studies which have
shown biallelic mutation of SLC26A4 to be correlated with
Table 2 List of homozygous and compound heterozygous variants detected in this study
Mutation Mutation Type Elder sister Younger sister Father Mother
Mutations shared by two affected siblings
LDB3: ENST00000429277:c.1384C > A:p.Pro462Thr Hom AA AA CA CA
DUOX2: ENST00000603300:c.1588A > T:p.Lys530* CompHet TA TA TA TT
DUOX2: ENST00000603300:c.3329G > A:p.Arg1110Gln CompHet CT CT CC CT
COL22A1: ENST00000303045:c.923A > G:p.Glu308Gly CompHet TC TC TC TT
COL22A1: ENST00000303045:c.2101A > G:p.Met701Val CompHet TC TC TT TC
Mutations detected in elder sister only
TECPR2: c.1477C > T:p.Pro493Ser CompHet CT CC CT CC
TECPR2: c.1457C > T:p.S486Leu CompHet CT CT CC CT
CHRD: c.2261C > G:p.Ala754Gly CompHet CG CC CG CC
CHRD: c.993G > C:p.Gln331His CompHet GC GG GG GC
CYP4V2: ENST00000378802:c.237G > T:p.Gln79Asp CompHet GT GG GT GG
CYP4V2: ENST00000378802:c.367A > G:p.Met123Val CompHet AG AA AG AA
CYP4V2: ENST00000378802:c.780C > G:p.Ile260Met CompHet CG CG CC CG
RAPGEF6: ENST00000509018:c.664C > T:p.Arg222Cys CompHet GA GG GA GG
RAPGEF6: ENST00000509018:c.1963A > G:p.Thr655Ala CompHet TC TT TT TC
MUC22: ENST00000561890:c.2998_299AC CompHet GA/AC GA_HOM GA-HOM GA/AC
MUC22: ENST00000561890:c.3441_3442AG CompHet CA/AG CA/AG CA/AG CA_HOM
MUC22: ENST00000561890:c.3493A > C:p.I1165Leu CompHet AC AC AC AA
Mutations detected in younger sister only
CR1: ENST00000367049:c.7310 T > C:p.Leu2437Pro CompHet TC TC TC TT
CR1: ENST00000367049:c.6919G > A:p.Gly2307Arg CompHet GG GA GG GA
MUC16: ENST00000397910:c.38825A > G:p.Gln12942Arg CompHet TT TC TC TT
MUC16: ENST00000397910:c.11458A > G:p.T3820Ala CompHet TT TC TT TC
MUC16: ENST00000397910:c.7201G > T:p.Ala2401Ser CompHet CC CA CA CC
FRAS1: ENST00000264895:c.1471C > T:p.R491Trp CompHet CT CT CC CT
FRAS1: ENST00000264895:c.11893A > G:p.Asn3965Asp CompHet AA AG AG AA
Abbreviations: Hom homozygous, CompHet compound heterozygous
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bilateral EVA, while monoallelic mutation or zero
mutation of SLC26A4 correlated with unilateral EVA
[35, 39, 41], we did not observe the association of
this monoallelic SLC26A4 mutation and the severity
of cochlea anomalies. Both sisters with SLC26A4
monoallelic mutation had incomplete partition type II
abnormalities and presented with bilateral hearing loss
at the age of 13 and 8 years old respectively.
As the evidence showing SLC26A4 and/or GJB2
monoallelic mutation was not sufficient to cause PDS in
this family, we explored the implication of other possible
causal mutations. Our analysis discovered pathogenic
heterozygous mutation in another deafness associated
gene, SCARB2 (MIM #602257), in both siblings and
mother. SCARB2 encodes for lysosomal integral mem-
brane protein type 2, which is involved in membrane
transportation and the reorganization of endosomal and
lysosomal compartment. An earlier study has shown loss
of function in SCARB2 being implicated in hearing loss,
whereby the SCARB2 knockout mice manifested coch-
lear deafness, which is associated with massive spiral
ganglion neuron losses, concomitant with loss of the
Fig. 1 Sanger validation of DUOX2 compound heterozygous mutations (ENST00000603300:c.1588A > T:p.Lys530* and c.3329G > A:p.Arg1110Gln),
SLC26A4 (ENST00000265715:c.1343C > T, p.Ser448Leu), GJB2 (ENST00000382844:c.368C > A, p.Thr123Asn), and SCARB2 (ENST00000264896:c.914C > T,
p.Thr305Met) heterozygous mutations. The arrow shows the site of the changes
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inner and outer hair cells and a strongly impaired cap-
acity to generate an endocochlear potential [42]. Beyond
that, mutational analysis also identified that SCARB2 mu-
tation was associated with hearing impairment [43, 44].
Given that both sisters inherited similar SCARB2,
SLC26A4 and GJB2 mutations from their unaffected par-
ents, our data supports the notion that a combination of
these 3 heterozygous mutations may led to bilateral hear-
ing loss in these 2 sisters.
In addition, we detected a compound heterozygous
mutation in DUOX2 (p.Lys530* & p.Arg1110Gln) in
both siblings. DUOX2 encodes for a key enzyme re-
quired to generate hydrogen peroxide (H2O2) which is
essential for thyroid hormone synthesis and normal thy-
roid function [45, 46]. It has been well documented that
mutations in DUOX2 are associated with congenital
hypothyroidism [47–51]. For instance, biallelic and trial-
lelic mutations in DUOX2 are associated with perman-
ent congenital hypothyroidism, whilst mononoallelic
mutation caused transient congenital hypothyroidism
[49, 51]. Mutation p.Lys530* and p.Arg1110Gln in
DUOX2 were found in patients with transient congenital
hypothyroidism [49]. Earlier studies also have shown
that p.Arg1110Glu in DUOX2 reduced H2O2 production
(5–9%, P < 0.01), hence contributed towards transient
congenital hypothyroidism [48, 52]. Our analysis sug-
gested that the DUOX2 compound heterozygous muta-
tions in both sisters may be involved in permanent
congenital hypothyroidism, and correlated with significant
goiter manifestation at a young age. DUOX2 mutational
screening may be useful to detect thyroid dysfunction as
compared to perchlorate discharge test, and to differenti-
ate between PDS and other hearing loss diseases.
Taken together, our analysis suggested that PDS in this
family could be a complex polygenic disorder which at-
tributed to a combination of 3 heterozygous mutations
implicated in deafness-related genes (SLC26A4:p.Ser448-
Leu; GJB2:p.Thr123Asn; SCARB2:p.Thr305Met), as well
as a compound heterozygous mutation implicated in
gene associated with thyroid function (DUOX2:p.Lys530*
& p.Arg1110Gln).
Conclusions
In summary, our findings showed that exome sequencing
has enabled the identification of new candidate causal
genes underlying PDS, and suggested that PDS could be a
complex heritable polygenic disorder. In this case study,
we postulated that a combination of SLC26A4, GJB2 and
SCARB2 heterozygous mutations may be implicated in
deafness, whilst DUOX2 compound heterozygous muta-
tions may be contributed towards thyroid dysfunction.
Screening of additional family members and additional
PDS cases may be required to strengthen the usefulness of
SLC26A4, GJB2, SCARB2 and DUOX2 as candidate diag-
nostic biomarkers for PDS.
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